These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38597738)

  • 61. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.
    Chen L; Tao X; Zeng M; Li Y; Han J; Wang Y; Liu Y; Shi R; Su R; Xu L; Mi Y
    J Med Virol; 2024 Apr; 96(4):e29613. PubMed ID: 38634477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1939-1949. PubMed ID: 38725327
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Sep; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of healthy lifestyles with risk of all-cause and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease: results from the DFTJ cohort.
    Deng Q; Zhang Y; Guan X; Wang C; Guo H
    Ann Med; 2024 Dec; 56(1):2398724. PubMed ID: 39247937
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection.
    Roderburg C; Waldschmidt D; Leyh C; Krieg S; Krieg A; Luedde T; Loosen SH; Kostev K
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592145
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis.
    Nso N; Mergen D; Ikram M; Macrinici V; Hussain K; Lee K; Ugwendum D; Trimingham M; Balasubramanian S; Sam R; Njei B
    Curr Probl Cardiol; 2024 Jun; 49(6):102569. PubMed ID: 38599554
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevalence of Steatotic Liver Disease Subtypes and Association With Metabolic Risk Factors in the Framingham Heart Study.
    Sun N; Prescott B; Ma J; Mohanty A; Long MT; Walker ME
    Clin Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38857746
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease.
    García-Mateo S; Martínez-Domínguez SJ; Gargallo-Puyuelo CJ; Gallego B; Alfambra E; Aso MC; Martinez-Micaelo N; Amigó N; Martínez-García J; Baptista PM; Sanz B; Ballesta S; Espinosa J; Tejero C; Gomollón F
    Med Clin (Barc); 2024 May; 162(9):409-416. PubMed ID: 38423940
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies.
    Zhou BG; Jiang X; She Q; Ding YB
    Eur J Clin Invest; 2024 Nov; 54(11):e14276. PubMed ID: 38943276
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.
    Jiang M; Pan Z; George J; Eslam M
    Hepatol Int; 2024 Aug; ():. PubMed ID: 39196505
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
    Yang AH; Tincopa MA; Tavaglione F; Ajmera VH; Richards LM; Amangurbanova M; Butcher C; Hernandez C; Madamba E; Singh S; Bettencourt R; Schnabl B; Sirlin CB; Loomba R
    Gut; 2024 Aug; ():. PubMed ID: 39117370
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
    J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 77. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
    Castillo-Núñez Y; Almeda-Valdes P; González-Gálvez G; Arechavaleta-Granell MDR
    Curr Diab Rep; 2024 Jul; 24(7):158-166. PubMed ID: 38700793
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.
    Zhao JF; Zhou BG; Lv Y; Teng QP; Wang XM; Li XY; Ding Y
    Front Oncol; 2024; 14():1368965. PubMed ID: 39045565
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
    Lee JH; Park J; Ahn SB
    Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
    Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
    Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.